肝硬化合并AKI启动RRT患者的预后:病因与肝移植资格的影响
分析显示,在未列入肝移植的患者中,6个月生存率仅15%;无论诊断肝肾综合征还是急性肾小管坏死,死亡率均极高,且AKI病因与死亡风险无显著关联。
要点
- 未列入肝移植的肝硬化AKI患者启动RRT后6个月生存率仅15%。
- 未列入肝移植者中,肝肾综合征与急性肾小管坏死的死亡风险无显著差异。
- 已列入肝移植者中48%接受了肝移植,肝肾综合征与急性肾小管坏死的无移植生存期亦无显著差异。
核心结论
- 在需要RRT的肝硬化AKI患者中,AKI病因(肝肾综合征 vs 急性肾小管坏死)与死亡率无显著关联。
- 未列入肝移植的患者中,无论肝肾综合征还是急性肾小管坏死,死亡率均极高。
研究设计与样本
- 采用多因素回归和生存分析,按肝移植列入状态分层。
主要发现
- 未列入肝移植者中,启动RRT后6个月生存率为15%(51/341)。
- 未列入肝移植者中,肝肾综合征中位生存期21天(IQR 8-70),急性肾小管坏死中位生存期12天(IQR 3-43),P=0.25。
- 已列入肝移植者中,48%(63/131)接受了肝移植;肝肾综合征无移植生存期中位15天(IQR 5-37),急性肾小管坏死14天(IQR 4-31),P=0.60。
- 调整Cox模型按移植列入状态分层后,肝肾综合征与急性肾小管坏死的死亡风险无显著差异(未列入者HR 0.81,95%CI 0.59-1.11;已列入者HR 0.73,95%CI 0.44-1.19)。
临床怎么用
- 对未列入肝移植的肝硬化AKI患者启动RRT时,应认识到其6个月生存率极低,需与患者及家属充分沟通预后。
- AKI病因(肝肾综合征或急性肾小管坏死)不应作为判断预后的主要依据,两者死亡率均高。
局限性
- 回顾性研究设计,可能存在选择偏倚和混杂。
- 仅纳入五家医院(含一家肝移植中心),结果外推需谨慎。
- 未报告RRT指征、剂量及后续治疗调整等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Literature on the prognosis of patients with cirrhosis who require RRT for AKI is sparse and is confounded by liver transplant eligibility. An update on outcomes in the nonlisted subgroup is needed. Our objective was to compare outcomes in this group between those diagnosed with hepatorenal syndrome and acute tubular necrosis, stratifying by liver transplant listing status. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Retrospective cohort study of patients with cirrhosis acutely initiated on hemodialysis or continuous RRT at five hospitals, including one liver transplant center. Multivariable regression and survival analysis were performed. RESULTS: Four hundred seventy-two subjects were analyzed (341 not listed and 131 listed for liver transplant). Among nonlisted subjects, 15% (51 of 341) were alive at 6 months after initiating RRT. Median survival was 21 (interquartile range [IQR], 8, 70) days for those diagnosed with hepatorenal syndrome and 12 (IQR, 3, 43) days for those diagnosed with acute tubular necrosis (P=0.25). Among listed subjects, 48% (63 of 131) received a liver transplant. Median transplant-free survival was 15 (IQR, 5, 37) days for those diagnosed with hepatorenal syndrome and 14 (IQR, 4, 31) days for those diagnosed with acute tubular necrosis (P=0.60). When stratified by transplant listing, with adjusted Cox models we did not detect a difference in the risk of death between hepatorenal syndrome and acute tubular necrosis (hazard ratio [HR], 0.81; 95% confidence interval [95% CI], 0.59 to 1.11, among those not listed; HR, 0.73; 95% CI, 0.44 to 1.19, among those listed). CONCLUSIONS: Cause of AKI was not significantly associated with mortality in patients with cirrhosis who required RRT. Among those not listed for liver transplant, mortality rates were extremely high in patients both with hepatorenal syndrome and acute tubular necrosis. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2017_11_09_CJASNPodcast_18_1_A.mp3.
引用
- Allegretti AS, Parada XV, Eneanya ND, et al. Prognosis of Patients with Cirrhosis and AKI Who Initiate RRT. Clin J Am Soc Nephrol. 2017. PMID: 29122911. doi:10.2215/CJN.03610417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。